Ceribell, Inc. (CBLL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed from Bank of America Securities reiterated a Buy rating on the stock and has a $32.00 price target.
Travis Steed has given his Buy rating due to a combination of factors that highlight Ceribell, Inc.’s strong financial performance and strategic investments. The company reported a Q4 revenue of $18.5 million, surpassing the market’s expectation of $17.5 million, and provided a 2025 revenue guidance of $81-$85 million, which is higher than the market’s estimate of $81 million. This indicates a positive outlook for the company’s growth. Additionally, Ceribell’s ongoing investments in sales infrastructure, which began in Q3 2024 and are expected to continue through mid-2025, are anticipated to drive revenue growth beyond 2026 as more hospitals adopt their technology.
Moreover, the company’s gross margin for 2025 is projected to be in the mid to high 80% range, aligning with market expectations despite increased tariffs on materials from China. With higher-than-expected IPO proceeds, Ceribell is accelerating its hiring plans for R&D talent and investing in pipeline expansion to enhance its total addressable market. These strategic moves, coupled with an increase in stock-based compensation and a robust hiring plan for territory managers, underscore the company’s commitment to long-term growth and justify the Buy rating.
According to TipRanks, Steed is a 5-star analyst with an average return of 11.6% and a 67.16% success rate. Steed covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Becton Dickinson, and Dexcom.
Questions or Comments about the article? Write to editor@tipranks.com